Psoriatic arthritis combines painful joint inflammation ... affected joints often appear red and feel warm to the touch. This active inflammation distinguishes it from wear-and-tear arthritis ...

Medically reviewed by Stella Bard, MD Psoriatic arthritis (PsA) is a chronic (long-term) condition that includes symptoms of ...

A rheumatologist discusses how her understanding of chronic pain in PsA has evolved—and how it affects her approach to ...

Discover 5 insights about psoriatic arthritis from rheumatology experts, including pain management strategies, treatment ...

Researchers argued that more active screening of people at high risk of psoriatic arthritis needs to take place, using more ...

(RTTNews) - Drug major Johnson & Johnson (JNJ) announced Friday positive results from the TREMFYA (guselkumab) Phase 3b APEX study in adults living with active psoriatic arthritis or PsA ...

Apremilast treatment in patients with psoriatic arthritis leads to favorable changes in body composition and improves disease ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

—In a study of more than 600 psoriatic arthritis (PsA) patients conducted in a real-world setting, investigators recently sought to identify phenotype clusters and how they’re associated with ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...